Articles tagged with Prostate Cancer
Researchers found that areas with low environmental quality had stronger associations with late-stage prostate cancer diagnoses, particularly in Black men. The study suggests that addressing environmental factors such as land, water, and sociodemographic variables could improve treatment outcomes.
Researchers at UVA Cancer Center have unveiled new insights into how hormones known as androgens act on cells, which could lead to improved treatments for prostate, ovarian, and breast cancers. The study found that a complex signaling system regulates androgen receptor activity, using an enzyme called Parp7.
Researchers enrolled 50 Black and 50 white men with advanced prostate cancer to test hormone therapy abiraterone acetate plus prednisone. They found that Black men's PSA levels dropped further and more frequently, but disease progression and survival times were similar.
A new clinical trial is investigating the effectiveness of white button mushroom tablets in regulating immune systems and reducing prostate-specific antigen (PSA) levels. The study aims to recruit 132 male participants with recurrent prostate cancer, with results indicating potential benefits against prostate cancer.
A new study found a 36% decrease in prostate cancer diagnoses in Sweden during the first pandemic wave, with most pronounced declines among men aged 75 and over. The number of patients receiving curative treatment remained unaffected, suggesting that healthcare prioritized cancer care during the pandemic.
Researchers have developed a new urine test called ExoGrail, which shows how aggressive prostate cancer is and can reduce unnecessary biopsies. The test uses biomarkers to provide risk scores and identify patients who need invasive biopsies.
Researchers have discovered a new way to transform tissue surrounding prostate tumors to help the immune system fight cancer. The technique, called epigenetic reprogramming, could lead to improvements in immunotherapy treatments for prostate cancer.
Researchers at CU Cancer Center have discovered that tumor-suppressing genes MAP3K7 and CHD1 deletion increases androgen receptor signaling, making patients less responsive to anti-androgen therapy. This knowledge could lead to personalized treatment approaches for men with aggressive prostate cancer.
Tumor gene profiling decreases patient acceptance of active surveillance among men with clinically similar prostate cancers and low health literacy, a new study found. The study suggests that education on prostate cancer treatment options is needed for this population.
Research reveals associations between circulating tumor cell (CTC) mutations and clinical outcomes in metastatic castrate-resistant prostate cancer (mCRPC). The study identified novel genetic alterations linked to response to AR inhibitors, including gains of ATM, NCOR2, and HSD17B4, which were associated with sensitivity to treatment.
Researchers at Duke University Medical Center identified a key reason hormone therapies fail and proposed a new treatment strategy directly targeting the cancer's fuel source, glutamine. By inhibiting glutamine utilization, tumor growth is successfully inhibited in studies using prostate cancer cell lines and animal models.
A mouse study suggests that white button mushroom extract can suppress androgen receptor activity in prostate cancer cells. The study also found that mice treated with the extract experienced reduced prostate tumor growth and decreased levels of PSA in their blood.
Researchers discovered microRNA-4287 inhibits prostate cancer's progression and metastasis, leading to increased cell cycle arrest. The study found miR-4287 specifically targets SLUG and CD44, suggesting a potential diagnostic and therapeutic tool against advanced prostate cancer.
A new study suggests that targeted screening for prostate cancer could prevent up to 16% of prostate cancer deaths and reduce overdiagnosis by 27%. The study, led by UCL researchers, recommends screening men with a high genetic risk profile using an MRI scan before biopsy.
A $1.06 million grant has been awarded to LSU Health New Orleans School of Medicine to explore a new treatment for Castrate Resistant Prostate Cancer (CPRC). The research focuses on the role of Prostate Derived ETS Transcription Factor (PDEF) in prostate cancer, with the goal of identifying novel targets for intervention.
The Cleveland African American Prostate Cancer Project aims to reduce health disparities by increasing prostate cancer screening among African American men. The project will develop and implement a comprehensive, sustainable program to screen for prostate cancer using barbershops as community hubs.
A genetic tool has been validated to estimate age of onset for aggressive prostate cancer in diverse ethnic/racial groups, with improved performance in men of African ancestry. The polygenic hazard score demonstrated excellent performance across European, Asian, and African genetic backgrounds.
Research from Baylor College of Medicine reveals that inhibiting MAPK4 can simultaneously activate and inhibit key cellular signaling pathways driving prostate cancer growth, suggesting a novel therapeutic strategy. This approach may provide a more effective treatment for advanced prostate cancer.
A new review highlights biological differences in prostate cancer development across ethnicities, identifying potential improvements for African American men. The study aims to reduce incidence and mortality rates by leveraging these differences.
A cross-disciplinary study combines canine olfaction with other detection methods to improve prostate cancer diagnosis. Dogs showed 71% sensitivity in detecting aggressive prostate cancer from urine samples, and an artificial neural network replicated their performance using spectroscopy data analysis.
Scientists at MIT develop system that detects chemical and microbial content of air samples with greater sensitivity than a dog's nose. The miniaturized detection system, coupled with machine-learning process, can identify distinctive characteristics of disease-bearing samples, matching success rates of dogs in detecting prostate cancer.
Researchers created a model to identify patients with high-risk prostate cancer who will benefit from the PSMA PET scan. The study found that patients with a Gleason score of 9 or 10 and high percent positive cores are most likely to benefit from the scan.
New research from Edith Cowan University found that exercise helps men with prostate cancer reduce symptoms of depression and anxiety, regardless of the type or intensity of exercise. The study suggests that supervised exercise is more beneficial than unsupervised exercise in reducing psychological distress.
A urine test has been found to be extremely accurate at detecting aggressive prostate cancer with few false negatives. The test avoids unnecessary biopsies for patients with slow-growing or no cancer, reducing costs and invasive procedures.
A retrospective study found that melatonin significantly improved the median overall survival of prostate cancer patients with poor prognosis, reducing mortality risk by more than twice. The antitumor effects of melatonin are fully realized in treating PCa patients with unfavorable tumor progression factors.
A new study discovered that Black men's tumors have a higher proportion of plasma cells, which correlates with improved cancer survival after surgery. This finding suggests that plasma cells may be key drivers of prostate cancer immune-responsiveness and could lead to personalized treatment options for men of all races.
The new risk score, developed by HKBU and CUHK researchers, uses urine spermine levels to estimate a patient's risk of developing prostate cancer. The test has been shown to accurately identify high-risk patients and help reduce unnecessary biopsies.
A new study published in the Journal of Nuclear Medicine found that combining radionuclide therapy with immunotherapy can slow prostate cancer progression and increase survival time. The treatment promotes prostate cancer immunogenicity, making tumors more receptive to immunotherapy.
A Phase III clinical trial has shown that Magnetic Resonance Imaging (MRI) with targeted biopsies can detect clinically significant prostate cancer more accurately and reduce the need for invasive procedures. The study found that MRI-TBx can help avoid unnecessary treatments and improve patient outcomes.
A new ultrasound technique called MRI-guided focused ultrasound ablation (MRgFUS) effectively treats intermediate-risk prostate cancer with minimal side effects. Treatment was successfully completed in all 44 men, with no major adverse events and 93% disease-free at the treatment site.
A team of researchers developed an AI analysis method to diagnose prostate cancer from urine within twenty minutes with almost 100% accuracy. The technique utilizes multiple cancer factors in urine to enhance diagnostic accuracy innovatively.
Scientists at Thomas Jefferson University discovered that CRY-1, a regulator of circadian rhythms, promotes tumor progression by altering DNA repair mechanisms. The study found that CRY-1 is strongly associated with poor outcomes in late-stage prostate cancers.
A pooled data analysis suggests that drinking several cups of coffee daily may be associated with a lower risk of developing prostate cancer. The study found that each additional daily cup was linked to a relative risk reduction of nearly 1%, with the highest intake group showing a 9% lower risk compared to the lowest.
A study by researchers at UCLA Jonsson Comprehensive Cancer Center found that MRI frequently underestimates the size of prostate tumors, which can lead to undertreatment. The accuracy of treatment depends on precise measurements of both tumor size and PI-RADS score.
A new study found that a Mediterranean-style diet may help slow the progression of prostate cancer in men who are not seeking immediate treatment. Men with localized prostate cancer who followed a more plant-based diet had a lower risk of cancer growth or advancement, regardless of their age, PSA levels, or tumor volume.
Australian researchers have discovered a new mechanism by which prostate cancer cells can adapt and evolve into more aggressive forms, making them resistant to treatment. The study highlights the importance of targeting microRNA-194 to slow down and inhibit the growth of prostate cancer models with neuroendocrine features.
A large-scale genetic analysis of over 200,000 men from diverse backgrounds identified 86 new risk factors for prostate cancer. The study found significant disparities in risk between racial and ethnic groups, with African American men inheriting twice the risk of European American counterparts.
Researchers found that blocking the androgen receptor reduces coronavirus infection in mice and cellular models. Anti-androgen treatments are already FDA-approved, opening up potential COVID-19 treatment options.
Researchers identified genomic heterogeneity and immune content scores that predict lethal outcomes in grade 4/5 prostate cancer patients. The study found that approximately 25% of these patients were more likely to benefit from targeted treatment strategies.
Researchers investigated delaying radical prostatectomy surgery for up to six months in patients with high-risk prostate cancer. The results indicate that delaying surgery may be associated with worse outcomes, highlighting the need for personalized treatment decisions.
The new PSMA PET imaging technique has been shown to detect significantly more prostate lesions than current standard-of-care techniques. This breakthrough could lead to better treatment outcomes and more precise care for men with prostate cancer.
Researchers found that providing genetic feedback to high-risk individuals improves their understanding and perceived value of the information. The study aims to improve healthcare by enabling personalized prevention plans and treatments for people with hereditary predispositions.
A study of 514 men undergoing active surveillance for early-stage prostate cancer found that those with negative biopsies had more favorable clinical characteristics and excellent long-term outcomes. Negative biopsies indicated low-volume disease with lower rates of disease progression, supporting continued active surveillance.
Researchers identified a genetic signature in localized prostate cancer that can predict metastasis and treatment response. The signature, called META-16, was highly effective at predicting time to metastasis and response to anti-androgen therapy.
A recent study found that men undergoing active surveillance for low-risk and intermediate-risk prostate cancer have very low rates of cancer spread and death from prostate cancer. The study analyzed 1,450 patients and identified three factors that affect the risk of metastases: Gleason grade, PSA velocity, and multiparametric MRI.
African American men with low-risk prostate cancer treated under active surveillance have a higher risk of disease progression and mortality compared to non-African American patients. The study's findings suggest that racial disparities exist in the clinical outcomes of prostate cancer treatment with active surveillance.
African American men with low-risk prostate cancer can safely undergo active surveillance without increased risk of disease progression, metastasis, or death. The study found that African Americans experienced higher rates of disease progression and treatment compared to white men, but comparable mortality rates.
Research reveals that African American men's prostate cancer tumors have higher frequencies of certain genetic alterations compared to white men. These alterations may contribute to more aggressive disease and higher mortality rates among Black men.
The study found that 5-year freedom from biochemical failure stands at 68%, comparable to other salvage modalities. At 10 years, the rate dropped to 54%. Late Grade 3 gastrointestinal and genitourinary adverse events occurred in 14% of participants.
Researchers found that fluorine-18-labeled fluciclovine PET/MRI accurately identified prostate cancer lesions, suspicious lymph nodes, and detected nodal metastases not visible on conventional imaging. The technology also showed promise in evaluating response to androgen deprivation therapy.
The study found that MFS was strongly correlated with OS (τ = 0.86), while BF and DM were only moderately and weakly correlated with OS, respectively. The analysis suggests that researchers should be cautious when inferring clinical benefit from studies using biochemical failure as a surrogate for overall survival.
A new study found that adding advanced PET scans to radiation plans for prostate cancer increases disease-free survival rates. After three years, 75.5% of patients treated with the additional imaging were still cancer-free, compared to 63% in the control group.
A Winship Cancer Institute study shows that advanced molecular imaging with fluciclovine improves disease-free survival rates for patients with recurring prostate cancer after prostatectomy. The trial found a 12% better cancer control rate at three years, persisting at four years.
A new staging system called STAR-CAP has been developed to predict outcomes and inform treatment decisions for men with non-metastatic prostate cancer. The system, which uses patient, tumor, and outcome data from nearly 20,000 patients, has been validated and shows strong prognostic power.
African American men are more susceptible to prostate cancer due to immune-oncologic differences, which can be exploited for personalized treatment options. The study found elevated immune pathways and higher expression of T lymphocytes in African American prostate tumors, suggesting better responses to radiotherapy and immunotherapy.
Rutgers researchers identified 16 gene markers that collaborate to cause metastatic prostate cancer, enabling the prediction of high-risk patients. These markers can help inform personalized therapy and improve outcomes for those with advanced disease.
A study by Tampere University and the University of Oxford has identified a principle that explains how prostate cancer spreads, with implications for liquid biopsy. Researchers discovered that not all subclones spread to the entire body, and some may be confined to the prostate.
A new intraoperative imaging technique, Cerenkov luminescence imaging (CLI), can accurately assess surgical margins during radical prostatectomy by detecting prostate cancer tissue at the resection margin. CLI has shown high diagnostic accuracy in detecting tumor cells and positive surgical margins.
Researchers at Kanazawa University discovered that thymoquinone selectively kills prostate cancer cells with a SUCLA2 gene deletion. This finding offers a promising therapeutic option for advanced prostate cancer patients who have developed resistance to hormone therapy.
The availability of mpMRIp in Australia has led to a significant reduction in prostate biopsies by an average of 354.7 per month. This is estimated to save $13.2 million annually, making it a financially sensible policy from a healthcare perspective.